WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
StemTek and Biopredic International partner to deliver assay ready liver models
Both companies plan to combine their respective technologies to deliver storable assay-ready 3D liver models for toxicology testing to reduce time and cost in new drug development.
August 21, 2018, Bilbao, Spain and Saint Grégoire, France — StemTek and Biopredic International are joining forces to design convenient, ready to use storable systems for toxicology screening on 3D liver cell models. 3D cell culture technology recapitulates the natural architecture of the tissue in a convenient laboratory format, producing more predictive data for in vivo tests. This technology allows a better understanding of the interaction of candidate compounds in areal physiological model, thus reducing drug failures. [Read more…]
Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal
SAN CARLOS, Calif., Aug. 22, 2018 — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapy from BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the roll-in cohort reported. The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D. [Read more…]
California Cryobank And CBR Combine To Create A Leading Life Sciences Platform
LOS ANGELES, Aug. 6, 2018 — California Cryobank, the world’s leading donor sperm and donor egg bank, announced today that it has been acquired by GI Partners, a private equity investment firm, from leading healthcare investors Longitude Capital and NovaQuest Capital.
In a separate transaction, GI Partners has also completed its acquisition of Cord Blood Registry (CBR), the world’s largest stem cell collection and storage company, from AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). [Read more…]
Former Stem Cell Patient Announces Foundation’s New Initiative to Guide Stem-Cell Companies, Clinics into FDA “RMAT” Process
Doug Oliver advised Congress on 21st Century Cures Act, leads foundation’s growing network of experts to help clinics pursue FDA approval
“I love what you’re doing and remember those early fateful days where I got you together with Senator Alexander … You reached out to me early on, and with that we’re helping hundreds of thousands, and eventually millions of people through your hard work.”
– Former U.S. Senate Majority Leader Bill Frist, M.D. [Read more…]
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 116
- Next Page »